US Clinical Practice Experience with Eculizumab in Myasthenia Gravis: Acute Clinical Events and Healthcare Resource Utilization

US Clinical Practice Experience with Eculizumab in Myasthenia Gravis: Acute Clinical Events and Healthcare Resource Utilization

Abstract Background and Objective The terminal complement inhibitor eculizumab is approved in the USA for the treatment of patients with acetylcholine receptor antibody-positive generalized myasthenia gravis (MG). The ELEVATE study aimed to examine clinical-practice outcome data on eculizumab effect...

Full description

Saved in:
Bibliographic Details
Main Authors: Richard J. Nowak, Ali A. Habib, Andrew J. Klink, Srikanth Muppidi, Anju Parthan, S. Chloe Sader, Alexandrina Balanean, Ajeet Gajra, James F. Howard, ELEVATE Study Group
Format: Article
Language:English
Published: Adis, Springer Healthcare 2024-10-01
Series:Drugs - Real World Outcomes
Online Access:https://doi.org/10.1007/s40801-024-00457-8
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items